

\$%^Dialog,HighlightOn=%%%;HighlightOff=%%%;

Connecting via Winsock to Dialog

Logging in to Dialog

Trying 31060000009998...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

ENTER PASSWORD:

Welcome to DIALOG

Dialog level 04.20.00D

Last logoff: 06jan05 10:56:25

Logon file001 10jan05 13:05:33

*** ANNOUNCEMENT ***

--Important Notice to Freelance Authors--

See HELP FREELANCE for more information

NEW FILES RELEASED

***German Patents Fulltext (File 324)

***Beilstein Abstracts (File 393)

***Beilstein Facts (File 390)

***Beilstein Reactions (File 391)

UPDATING RESUMED

Medline (Files 154 & 155)

REMOVED

***Info Sci & Tech Abs (File 202)

***Internet & Personal Comp Abs (File 233)

***CanCorp Financials (File 491)

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

>>> of new databases, price changes, etc. <<<

* * *

File 1:ERIC 1966-2004/Jul 21
(c) format only 2004 The Dialog Corporation

Set Items Description

Cost is in DialUnits

? b 155

10jan05 13:05:36 User208669 Session D2679.1

\$0.38 0.109 DialUnits File1

\$0.38 Estimated cost File1

\$0.38 Estimated cost this search

\$0.38 Estimated total session cost 0.109 DialUnits

File 155: MEDLINE(R) 1951-2005/Dec W4

(c) format only 2005 The Dialog Corp.

*File 155: Medline has resumed updating. Please see
HELP NEWS 155 for details.

Set Items Description

? s interferon and thymosin

83493 INTERFERON

1823 THYMOSIN

S1 142 INTERFERON AND THYMOSIN

? sort s1/all/py

S2 142 Sort S1/ALL/PY

? t s2/6/1-142

2/6/1

05916544 PMID: 6180073

Thymosin treatment modulates production of interferon.

1981

2/6/2

05913636 PMID: 6179891

Effects of NPT 15392 in vitro on human leukocyte functions.

1982

2/6/3

05885251 PMID: 6284520

Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by N alpha-desacetylthymosin alpha 1.

Mar 1982

2/6/4

05791619 PMID: 6174479

Effect of thymosin fraction 5 on the production of murine gamma interferon.

Feb 1982

2/6/5

06359890 PMID: 6670913

Influence of thymic hormones on mitogen-induced interferon production in lymphocytes. I. Augmentation of mitogen-induced immune interferon production by thymosin.

1983

2/6/6

06322076 PMID: 6228417

[Acquired immunodeficiency syndrome (AIDS). A 2-year review]

Erworbenes Immundefektsyndrom (AIDS). Eine Übersicht nach zwei Jahren.

Dec 16 1983

2/6/7

06302866 PMID: 6196449

Immunotherapy: the old and the new.

1983

2/6/8

06119932 PMID: 6404997

Gamma interferon production by different populations of human splenic lymphocytes.

1983

2/6/9

06062159 PMID: 6402312

Resistance and susceptibility to infection in inbred murine strains. II. Variations in the effect of treatment with thymosin fraction 5 on the release of lymphokines in vivo.

Jan 1983

2/6/10

06016956 PMID: 6184406

Thymosin peptides and lymphokines do not directly stimulate adrenal corticosteroid production in vitro.

Feb 1983

2/6/11

06803954 PMID: 6242001

Immunologic studies of the acquired immune deficiency syndrome: relationship of immunodeficiency to extent of disease.

1984

2/6/12

06803940 PMID: 6398648 Record Identifier: 036666; 00157440

Acquired immune deficiency syndrome: specific aspects of the disease in Haiti.

1984

2/6/13

06759495 PMID: 6085037

Biological response modifiers: preclinical evaluation and clinical activity.

1984

2/6/14

06710710 PMID: 6083885

[Thymus hormones--increased interferon production by human lymphocytes and therapeutic aspects]

Thymushormone--vermehrte Interferonbildung durch menschliche Lymphozyten und therapeutische Aspekte.

1984

2/6/15

06658774 PMID: 6209006

Immunological characterizations of patients with acquired immune deficiency syndrome, acquired immune deficiency syndrome-related symptom complex, and a related life-style.

Dec 1984

2/6/16

06615625 PMID: 6207037

Augmentation of mitogen-induced interferon production in lymphocytes by thymosin.

Jul 1984

2/6/17

06511010 PMID: 6201987

Contradictory results in interferon research.

1984

~~thymosin~~

2/6/18

06452161 PMID: 6420098

Resistance and susceptibility to infection in inbred murine strains. III.
Effect of thymosin on cellular immune responses of alloxan diabetic mice.

Jan 1984

2/6/19

07064056 PMID: 3879411 Record Identifier: 86153830

[Thymosin restoration of the interferon-synthesizing capacity of the splenocytes in mice undergoing stress exposure]

Vosstanovlenie timozinom interferonsinteziruiushchei sposobnosti splenotsitov myshei, perenessshikh stressornye vozdeistviia.

Nov-Dec 1985

2/6/20

06964465 PMID: 3851698

Modulation of natural killer activity by thymosin alpha 1 and interferon.
1985

NK (↑, adml.
(i.e., comp.)

2/6/21

06841690 PMID: 2861235

Evidence that thymosins and other biologic response modifiers can function as neuroactive immunotransmitters.

Aug 1985

2/6/22

06835285 PMID: 2408810

Immunopharmacologic bases of immunotherapy.

1985

2/6/23

06828284 PMID: 2408454

The effects of transfer factor in adjuvant diseases in rats.

Jan-Feb 1985

2/6/24

06801012 PMID: 2581368

[Effect of thymosin on interferon production and antiviral resistance in mice]

Vliianie timozina na produktsiiu interferona i protivovirusnuiu rezistentnost' myshei.

Jan-Feb 1985

2/6/25

06731863 PMID: 3918773

Biologicals and biological response modifiers: new approaches to cancer treatment.

1985

2/6/26

07183186 PMID: 3089752

Phase I trials of biological response modifiers.

1986

2/6/27

07101963 PMID: 3698881

[Induction of substances with thymosin-like activity and the potentiation of interferonogenesis in the mechanism of prodigiozan inhibition of 3-methylcholanthrene-induced blastomogenesis]

Induktsiia veshchestv s timozinopodobnoi aktivnost'iu i potentsirovanie interferonogeneza v mekhanizme tormozheniya prodigiozanom blastomogeneza, induktirovannogo 3-metilkholantrenom.

1986

2/6/28

07615412 PMID: 3500230

Differential expression of the human thymosin-beta 4 gene in lymphocytes,

macrophages, and granulocytes.

Dec 1 1987

2/6/29

07564427 PMID: 3116079

Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones.

Oct 1 1987

2/6/30

07465051 PMID: 3035761

Differentiation changes in cord blood T lymphocytes induced by synthetic C-terminal peptides of thymosin alpha 1.

1987

2/6/31

07440729 PMID: 3034098

Direct mapping of rare messenger RNAs by means of oligomer-directed ribonuclease H cleavage.

Mar 1987

2/6/32

07373882 PMID: 3029527

Corticosterone-releasing activity of immune mediators.

Mar 9 1987

2/6/33

08006572 PMID: 3146163

[The interferon system in viral hepatitis B]

Sistema interferona pri virusnom hepatite B.

Sep-Oct 1988

2/6/34

07976770 PMID: 3206562

[Immunomodulating and analgesic activity of synthetic fragments of various proteins and immunopeptides]

Immunomoduliruiushchaia i anal'geticheskaya aktivnost' sinteticheskikh fragmentov razlichnykh belkov i immunopeptidov.

Sep-Oct 1988

2/6/35

07963830 PMID: 2974170

[Immunoregulation during aging]

Immunoregolazione nell'invecchiamento.

Jul-Aug 1988

2/6/36

07785131 PMID: 2453772

Thymosin fraction 5 (TF5) stimulates secretion of adrenocorticotropic hormone (ACTH) from cultured rat pituitaries.

1988

2/6/37

07772883 PMID: 3369147

[The search for preparations suppressing the reproduction of the AIDS virus]

Poisk preparatov, podavliaiushchikh reproduktsiiu virusa SPID.

Jan-Feb 1988

2/6/38

07719586 PMID: 3127096

Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin beta 4 levels in patients with inflammatory bowel disease.

Apr 1988

2/6/39

08384885 PMID: 2557948

Immune modulation by aspirin during experimental rhinovirus colds.

Jan 1989

2/6/40

08315980 PMID: 2807622

Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice.

1989

2/6/41

08310799 PMID: 2509078

Effects of cytokines on human thymic epithelial cells in culture: IL1 induces thymic epithelial cell proliferation and change in morphology.
Nov 1989

2/6/42

08247642 PMID: 2504679

Aspirin and thymosin increase interleukin-2 and interferon-gamma production by human peripheral blood lymphocytes.
May-Jun 1989

2/6/43

08167963 PMID: 2543691

Interleukin-1 beta and other cytokines stimulate adrenocorticotropin release from cultured pituitary cells of patients with Cushing's disease.
Jul 1989

2/6/44

08056522 PMID: 2493778

[Immunostimulants--therapeutic aspects]
Immunostimulantien--Therapeutische Aspekte.
1989

2/6/45

08876854 PMID: 2090639

Structure and immunological properties of thymosin beta 9 Met, a new analog of thymosin beta 4 isolated from porcine thymus.
Dec 1990

2/6/46

08806382 PMID: 2126987

Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.
1990

2/6/47

09129103 PMID: 1721612

Effects of PCB (Aroclor 1254) on non-specific immune parameters in rhesus (*Macaca mulatta*) monkeys.

1991

2/6/48

09106104 PMID: 1958028

Interaction between thymic hormones and other immunomodulatory agents.

1991

2/6/49

08999813 PMID: 1874487

Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial.

Sep 1991

2/6/50

08829794 PMID: 2004759

Human thymosin-beta 4/6-26 gene is part of a multigene family composed of seven members located on seven different chromosomes.

Jan 1991

2/6/51

08783015 PMID: 1846821

The octapeptide corresponding to the region of the highest homology between alpha-interferon and thymosin-alpha 1 effectively competes with both cytokines for common high-affinity receptors on murine thymocytes.

Jan 28 1991

2/6/52

09978171 PMID: 1343739

[Biomolecules suppressing myelopoiesis]

Biomoleculas supresoras de la mielopoyesis.

1992

2/6/53

09549195 PMID: 1467368

Prothymosin alpha enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity.

Oct 1992

2/6/54

09453527 PMID: 1394439

Mixed interleukins and thymosin fraction V synergistically induce T lymphocyte development in hydrocortisone-treated aged mice.

Oct 1 1992

2/6/55

09441216 PMID: 1382288

Chronic hepatitis B and C. What is the status of drug therapy?

Sep 15 1992

2/6/56

09420551 PMID: 1514436

Therapies for hepatitis B virus: current status and future possibilities.

1992

2/6/57

09296097 PMID: 1582729

Thymosin alpha one restores murine T-cell-mediated responses inhibited by in vivo cocaine administration.

Jan 1992

2/6/58

09222666 PMID: 1545115

Prothymosin alpha enhances human and murine MHC class II surface antigen expression and messenger RNA accumulation.

Apr 1 1992

2/6/59

09882773 PMID: 7694023 Record Identifier: 091691; 00228498

Clinical aspects of hepatitis B virus infection.

Nov 27 1993

2/6/60

09846612 PMID: 8407692

Treatment of chronic viral hepatitis.

Jul 1993

2/6/61

09796482 PMID: 8353279

Prothymosin alpha gene expression correlates with proliferation, not differentiation, of HL-60 cells.

Aug 15 1993

2/6/62

09613556 PMID: 8435433

Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.

Jan 1993

2/6/63

10365551 PMID: 7872660

Prothymosin alpha augments deficient antitumor activity of monocytes from melanoma patients in vitro.

Nov-Dec 1994

2/6/64

10281246 PMID: 7526795

Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents.

Jul 1994

2/6/65

10146058 PMID: 8038356

Rolling review--the pathogenesis, diagnosis and management of viral hepatitis.

Apr 1994

2/6/66

10069456 PMID: 7910053

Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection.

1994

2/6/67

09986540 PMID: 8109588

New approaches to the treatment of chronic viral hepatitis B and C.
Jan 17 1994

2/6/68

13008539 PMID: 8652276

Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.

Dec 1995

2/6/69

12867847 PMID: 8845681

Local excision of retinal metastasis from cutaneous melanoma.

Jul-Sep 1995

2/6/70

12765076 PMID: 7549584

[Drug therapy in patients with chronic type B hepatitis]

Jun 1995

2/6/71

12632172 PMID: 7753051

The sequence 130-137 of human interferon-alpha 2 is involved in the competition of interferon, prothymosin alpha and cholera toxin B subunit for common receptors on human fibroblasts.

Apr 1995

2/6/72

12600351 PMID: 7716182

Treatment and prevention of chronic viral hepatitis.

Jan 1995

2/6/73

13647197 PMID: 11363915

Pot shots.

Sep 1996

2/6/74

13356711 PMID: 9030468

Thymus-derived peptides in the treatment of viral chronic hepatitis.
Nov-Dec 1996

2/6/75

13349814 PMID: 9026482

Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.

Nov 1996

2/6/76

13341546 PMID: 9014781

Adding interventions to interferon in chronic HCV infections.

Nov 1996

2/6/77

13334751 PMID: 9007707

Thymosin-alpha 1, but not interferon-alpha, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells.

Dec 1996

2/6/78

13202613 PMID: 8871880

Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B.

Jul 1996

2/6/79

13185283 PMID: 8855175

A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.

Oct 1996

2/6/80

13131218 PMID: 8799359

Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus.

Feb 1996

2/6/81

13021042 PMID: 8687090

Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial.

Mar-Apr 1996

2/6/82

12996736 PMID: 8672957

[Effects of interferon inducers on chemically-induced mutagenesis and carcinogenesis]

Vliianie induktorov interferona na khimicheski indutsirovannyi mutagenez i kantserogenez.

1996

2/6/83

13771875 PMID: 9467751

Prothymosin alpha 1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients.

Jun 1997

2/6/84

13715863 PMID: 9407357

Current therapeutic trends in therapy for chronic viral hepatitis.

Oct 1997

2/6/85

13616640 PMID: 9305680

Therapy of hepatitis C: other options.

Sep 1997

2/6/86

13455389 PMID: 9137512

Interferons alpha/beta and their receptors: place in the hierarchy of cytokines.

Mar 1997

2/6/87

14534376 PMID: 11365926

Two immune boosters against hepatitis C.

Nov 1998

2/6/88

14534088 PMID: 11365638

Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.

Jul 1998

2/6/89

14175998 PMID: 9875415

Current status of anti-HBV chemotherapy.

Apr 1998

2/6/90

14160269 PMID: 9858941

High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.

Sep-Oct 1998

2/6/91

14132498 PMID: 9831367

Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.

Oct 1998

2/6/92

14024172 PMID: 9722931

Cytokine-mediated apoptosis and inhibition of virus production and anchorage independent growth of viral transfected hepatoblastoma cells.

Aug 1998

2/6/93

13930619 PMID: 9629262

Thymic endocrinology.

May 1 1998

2/6/94

13837329 PMID: 9537454

Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.

Apr 1998

2/6/95

11204476 PMID: 11245080

Immunological approaches to the breakdown of hepatitis B viral persistence.

Jun 1998

2/6/96

14529992 PMID: 10530779

Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo.

Oct 18 1999

2/6/97

14375361 PMID: 10370473

[New therapeutic possibilities in the treatment of hepatitis B]

Nouvelles possibilites therapeutiques contre l'hepatite B.

1999

2/6/98

10505073 PMID: 10603734

[Characteristics of the hepatitis C virus and viral predictors of therapeutic response]

Charakteristika des Hepatitis-C-Virus und virale Prädiktoren der therapeutischen Intervention.

Nov 15 1999

2/6/99

11153934 PMID: 11214479

[The modern approach to wound treatment]

Savremeni pristup tretmanu rana.

Jul-Aug 2000

2/6/100

11089099 PMID: 11137613

Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.

Dec 2000

2/6/101

10794943 PMID: 10921382

Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection.

May 2000

2/6/102

10685886 PMID: 10803720

Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma.

Apr 2000

2/6/103

10663109 PMID: 10777179

Antiviral therapy of HBV- and HCV-induced liver cirrhosis.

Apr 2000

2/6/104

10648013 PMID: 10759236

A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.

Apr 2000

2/6/105

10615725 PMID: 10724345

Characterization of a 5'-flanking region supporting the transcription of mouse thymosin beta-4 in mouse NIH3T3 cells.

Jan 2000

2/6/106

11706970 PMID: 11819801

A randomized controlled clinical trial on the treatment of Thymosin al versus interferon-alpha in patients with hepatitis B.

Jun 2001

2/6/107

11706969 PMID: 11819800

Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Jun 2001

2/6/108

11696768 PMID: 11871510

Treatment of chronic hepatitis B.

Nov 2001

2/6/109

11510147 PMID: 11678618

Management of chronic hepatitis B infection: an update.

Jun 2001

2/6/110

11431560 PMID: 11529376

The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.

Jun 2001

2/6/111

11380075 PMID: 11472367

Profiling of genes expressed in human monocytes and monocyte-derived dendritic cells using cDNA expression array.

Jul 2001

2/6/112

11347717 PMID: 11436652

[The effect of IFN-alpha 2b-thymus peptides combined therapy in chronic hepatitis B]

Jun 2001

2/6/113

11300607 PMID: 11385968

Hepatitis B infection in China.

May 2001

2/6/114

11296504 PMID: 11380797

In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.

May 2001

2/6/115

11294983 PMID: 11381492

Thymosin alpha-1.

May 15 2001

2/6/116

15246911 PMID: 12579833

[Effect of recombinant prothymosin alpha on secretion of IFN-gamma, IFN-alpha and TNF-alpha in vitro]

May 2002

2/6/117

12103513 PMID: 12431200

Therapy of chronic hepatitis B: current challenges and opportunities.

Nov 2002

2/6/118

11894727 PMID: 12090542

Thymosin alpha1. SciClone Pharmaceuticals.

May 2002

2/6/119

11872991 PMID: 12066963

Chronic hepatitis B: current and future treatment options.

Jun 2002

2/6/120

11871159 PMID: 12063993

Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey.

May-Jun 2002

2/6/121

11846814 PMID: 12036599

Modulatory role of thymosin-alpha-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice.

Jul 3 2002

2/6/122

11812175 PMID: 12000599

Management of viral hepatitis B.

Feb 2002

2/6/123

11802231 PMID: 11990327

Thymosin alpha in the treatment of chronic hepatitis B: an uncontrolled open-label trial.

Mar-Apr 2002

2/6/124

11796819 PMID: 11982721

Treatment of chronic hepatitis B: case selection and duration of therapy.

Apr 2002

2/6/125

11796818 PMID: 11982720

Management of patients with chronic hepatitis B.

Apr 2002

2/6/126

11765358 PMID: 11945142

New therapies for the treatment of chronic hepatitis C.

2002

2/6/127

15894224 PMID: 12860172

Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma.

Aug 2003

2/6/128

15725684 PMID: 12820143

Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B.

Jul 2003

2/6/129

15431311 PMID: 12943166

Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials.

2003

2/6/130

15398426 PMID: 14625884

Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.

Nov-Dec 2003

2/6/131

12437957 PMID: 12837162

[Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome]

Jun 2003

2/6/132

17583632 PMID: 15482167

Thymalfasin for the treatment of chronic hepatitis B.

Feb 2004

2/6/133

17550064 PMID: 15546255

Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment.

Dec 2004

2/6/134

17550063 PMID: 15546254

Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis

B.

Dec 2004

2/6/135

17531412 PMID: 15529863

[Antiviral activity of human recombinant gamma-interferon and recombinant hybrid protein of tumor necrosis factor-alpha-thymosin-alpha1 on models of herpes-virus and cytomegalovirus infection in vitro]

Sep-Oct 2004

2/6/136

17419094 PMID: 15340532

[Clinical trial of sequential antiviral therapy for patients with chronic hepatitis B in China]

Mar 2004

2/6/137

17133413 PMID: 15468612

Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.

May 2004

2/6/138

17005508 PMID: 15313193

Regulated transcripts in the hippocampus following transections of the entorhinal afferents.

Sep 10 2004

2/6/139

16848972 PMID: 15242774

Interferon induces the interaction of prothymosin-alpha with STAT3 and results in the nuclear translocation of the complex.

Aug 1 2004

2/6/140

16658603 PMID: 15081103

Future trends in managing hepatitis C.

Mar 2004

2/6/141

15904365 PMID: 14738560

Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.

Jan 2004

2/6/142

11095361 PMID: 11366197

Hepatitis treatment update: new approvals, not much news.

? t s2/7/40 46 48 49 55

2/7/40

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

08315980 PMID: 2807622

Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice.

Favalli C; Mastino A; Jezzi T; Grelli S; Goldstein A L; Garaci E

Department of Experimental Medicine and Biochemistry, II University of Rome Tor Vergata, Italy.

International journal of immunopharmacology (ENGLAND) 1989, 11 (5) p443-50, ISSN 0192-0561 Journal Code: 7904799

Contract/Grant No.: CA24974; CA; NCI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

We have investigated the possibility of thymosin alpha 1 (TH) cooperating with alpha beta-interferon (IFN) in boosting natural killer (NK) activity in tumor-bearing, immunosuppressed mice in vivo. Treatment with a single injection of 30,000 IU of IFN 24 h before testing enhanced NK activity in tumor-bearing mice if the IFN was administered 9 days after tumor inoculation, when the animals have normal NK responsiveness. On the other hand, the same treatment led to lower or no improvement of NK responses if the treatment was given 13 or 17 days after tumor inoculation, at a time when tumor growth causes immunosuppression. However, combination treatment with TH (200 micrograms/kg) for 4 days, followed by IFN was found to restore normal NK cell activity. Selective depletion of antigen-positive cells showed that killer cells stimulated by combination treatment with TH

and IFN seem to bear phenotypic characteristics of NK cells. These studies provide the first documentation of a novel combination approach to reconstitution of immunosuppressed tumor-bearing mice using TH and IFN. We hypothesize that TH restores NK boosting activity by IFN by effecting the differentiation/induction of precursor populations of IFN-responsive cells.

Record Date Created: 19891219

Record Date Completed: 19891219

2/7/46

DIALOG(R)File 155 MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

08806382 PMID: 2126987

Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.

Garaci E; Mastino A; Pica F; Favalli C

Department of Experimental Medicine and Biochemical Sciences, II
University of Rome Tor Vergata, Italy.

Cancer immunology, immunotherapy - CII (GERMANY) 1990, 32 (3)
p154-60, ISSN 0340-7004 Journal Code: 8605732

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

A combination treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of murine interferon alpha/beta (3 x 10(4) international units/mouse), starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappearance of tumor burden in mice bearing Lewis lung carcinoma (3LL) tumor. The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself. The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologous 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells. A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.

Record Date Created: 19910329

Record Date Completed: 19910329

2/7/48

DIALOG(R)File 155: MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.

09106104 PMID: 1958028

Interaction between thymic hormones and other immunomodulatory agents.

Mastino A; Favalli C; Grelli S; Garaci E

Dipartimento di Medicina Sperimentale e Scienze Biochimiche, Universita
degli Studi Tor Vergata, Rome, Italy.

Annali dell'Istituto superiore di sanita (ITALY) 1991, 27 (1) p51-6,
ISSN 0021-2571 Journal Code: 7502520

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

We have investigated the effects of a combination in vivo treatment with thymosin alpha 1 (TA1) and murine alpha/beta interferon (IFN) on natural killer (NK) activity and on tumor growth in B-16 melanoma tumor-bearing mice. The results indicated that treatment with a single injection of IFN (3×10^{4} U 24 h before testing, enhanced NK activity in tumor-bearing mice if the test was performed 10 days after tumor inoculation, when the animals have normal NK responsiveness. On the other hand, the same treatment led to lower or no improvement of NK responses when the assay was performed 14 or 18 days after tumor inoculation, at a time when tumor growth caused NK-suppression. However, combination treatment with TA1 (200 micrograms/kg) for 4 days, followed by IFN was found to restore normal NK cell activity. On the other hand primary tumor growth was unaffected by combination therapy, while the same treatment with TA1 and IFN was able to significantly prolong survival time of B-16 tumor-bearing mice, when administered starting on day 6 after tumor inoculation. The last evidence, together with results on NK activity stimulation, indicates that combination therapy with TA1 and IFN could be an interesting approach to cancer immunotherapy.

Record Date Created: 19911230

Record Date Completed: 19911230

2/7/49

DIALOG(R)File 155: MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.

08999813 PMID: 1874487

Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial.

Mutchnick M G; Appelman H D; Chung H T; Aragona E; Gupta T P; Cummings G D; Waggoner J G; Hoofnagle J H; Shafritz D A

Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan 48201.

Hepatology (Baltimore, Md.) (UNITED STATES) Sep 1991, 14 (3) p409-15
ISSN 0270-9139 Journal Code: 8302946

Contract/Grant No.: CA32605; CA; NCI; FD-R-000096; FD; FDA

Comment in Hepatology. 1991 Sep;14(3) 567-9; Comment in PMID 1874501;

Comment in Hepatology. 1992 Dec;16(6):1507-8; Comment in PMID 1446904

Document type: Clinical Trial; Controlled Clinical Trial; Journal Article
Randomized Controlled Trial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Chronic hepatitis B is a severe and frequently progressive disease. We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg. Seven patients received thymosin fraction 5 or thymosin-alpha 1 and five patients received placebo twice weekly for 6 mo. By the conclusion of the study (1 yr), serum aminotransferase levels had improved significantly in thymosin-treated patients, but not in the placebo group. Six (86%) of the thymosin treated patients and one (20%) patient given placebo cleared hepatitis B virus DNA from serum (p less than 0.04, Fisher's exact test). After treatment, replicative forms of hepatitis B virus DNA were present in the liver specimens of four of five placebo-treated patients but in only one of seven thymosin-treated patients (p less than 0.04, Fisher's exact test). Response to thymosin therapy was associated with significant improvements in peripheral blood lymphocyte and CD3 and CD4 counts and in in vitro production of interferon-gamma over initial values. No significant side effects were observed in patients given thymosin or in placebo-treated patients. Clinical, biochemical and serological improvement in patients responding to thymosin were sustained during 26 +/- 3 mo of follow-up. The results of this pilot trial suggest that thymosin therapy promotes disease remission and cessation of hepatitis B virus replication in patients with chronic viral infection.

Record Date Created: 19910926

Record Date Completed: 19910926

DIALOG(R)File 155 MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.

09441216 PMID: 1382288

Chronic hepatitis B and C. What is the status of drug therapy?

Wright T L

Division of Gastroenterology and Hepatology, School of Medicine,
University of California, San Francisco.

Postgraduate medicine (UNITED STATES) Sep 15 1992, 92 (4) p75-82,
ISSN 0032-5481 Journal Code: 0401147

Document type: Clinical Trial; Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Chronic hepatitis remains difficult to treat. Use of interferon has been successful against both hepatitis B and C viruses, but the outcome of long-term administration has yet to be determined. Not all patients respond to interferon, however, and some have side effects that cause them to discontinue therapy. Dr Wright discusses the results of studies to evaluate therapy with alpha, beta, and gamma interferon as well as with other agents, such as ribavirin, thymosin, and ursodeoxycholic acid. (32 Refs.)

Record Date Created: 19921022

Record Date Completed: 19921022

? s hepatitis and s2

126085 HEPATITIS

142 S2

S3 62 HEPATITIS AND S2

? s fragment?

S4 267563 FRAGMENT?

? s s3 and s4

62 S3

267563 S4

S5 0 S3 AND S4

? s thymosin and dt=review? and py<1993

1823 THYMOSIN

1057875 DT=REVIEW?

9332251 PY<1993

S6 99 THYMOSIN AND DT=REVIEW? AND PY<1993

? t s6/6/1-10

6/6/1

09978171 PMID: 1343739

[Biomolecules suppressing myelopoiesis]

Biomoleculas supresoras de la mielopoyesis.

1992

6/6/2

09580231 PMID: 1485720

Thymic involution in aging. Prospects for correction.

Dec 26 1992

6/6/3

09527856 PMID: 1451325

Is thymosin alpha 1 a thymic hormone?

Dec 1992

6/6/4

09441216 PMID: 1382288

Chronic hepatitis B and C. What is the status of drug therapy?

Sep 15 1992

6/6/5

09420551 PMID: 1514436

Therapies for hepatitis B virus: current status and future possibilities.

1992

6/6/6

09353435 PMID: 1618589

Thymic regulation of the hypothalamic-pituitary-gonadal axis.

Apr 1992

6/6/7

09353434 PMID: 1618588

Thymic endocrinology.

Apr 1992

6/6/8

09234565 PMID: 1801474

[Interactions of circadian biorhythms of the immune and endocrine systems in mice]

Vzaimootnosheniiia sutochnykh bioritmov immunnoi i endokrinnoi sistem u myshei.

1991

6/6/9

09171223 PMID: 1776534

Role of thymic hormones in neuroimmunomodulation. Their use in patients with phobic disorders.

Oct 1991

6/6/10

09027256 PMID: 1891468

Prolactin and growth hormone in the regulation of the immune system.

Oct 1991

? s fragment?

S7 267563 FRAGMENT?

? s s6 and s7

99 S6

267563 S7

S8 4 S6 AND S7

? t s8/6/1-4

8/6/1

07996092 PMID: 2463798

[Thymic hormones]

Les hormones thymiques.

Aug 1988

8/6/2

06856151 PMID: 6399194

[Thymic hormones. Neuroendocrine interactions and clinical use in congenital and acquired immune deficiencies]

Les hormones thymiques. Interactions neuroendocriniennes et utilite clinique dans les deficits immunitaires congenitaux et acquis.

1984

8/6/3

05828972 PMID: 6280461

Thymic hormones and the immune system.

1981

8/6/4

05236047 PMID: 394636

Current status of thymosin research: evidence for the existence of a family of thymic factors that control T-cell maturation.

1979
? t s8/7/1-4

8/7/1
DIALOG(R)File 155: MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.

07996092 PMID: 2463798
[Thymic hormones]
Les hormones thymiques.
Monier J C; Auger C; Fabien N
Laboratoire d'Immunologie, UFR Alexis Carrel, Lyon.
Archives internationales de physiologie et de biochimie (BELGIUM) Aug
1988, 96 (3) pA2-26, ISSN 0003-9799 Journal Code: 0405355
Document type: Journal Article; Review; Review, Tutorial
Languages: FRENCH
Main Citation Owner: NLM
Record type: Completed
(151 Refs.)
Record Date Created: 19890221
Record Date Completed: 19890221

8/7/2
DIALOG(R)File 155: MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.

06856151 PMID: 6399194
[Thymic hormones. Neuroendocrine interactions and clinical use in congenital and acquired immune deficiencies]
Les hormones thymiques. Interactions neuroendocriniennes et utilite clinique dans les deficits immunitaires congenitaux et acquis.
Martin-Du-Pan R C
Annales d'endocrinologie (FRANCE) 1984, 45 (6) p355-68, ISSN 0003-4266 Journal Code: 0116744
Document type: Journal Article; Review ; English Abstract
Languages: FRENCH
Main Citation Owner: NLM
Record type: Completed
The epithelial cells of the thymus synthesize at least 30 different polypeptides: the thymic hormones. The structure of 4 of them is well known. They are named thymosin alpha 1, thymopoietin, thymulin and thymic humoral factor. Biological functions and secretion regulation of thymic hormones are described as well as the interactions between brain, thymus and endocrine glands. Blood levels and clinical usefulness of thymic

hormones are reviewed in different congenital or acquired immunodeficient states and in autoimmune diseases. (154 Refs.)

Record Date Created: 19850822

Record Date Completed: 19850822

8/7/3

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

05828972 PMID: 6280461

Thymic hormones and the immune system.

Wara D W

Advances in pediatrics (UNITED STATES) 1981, 28 p229-70, ISSN 0065-3101 Journal Code: 0370436

Contract/Grant No.: HD 00170-01; HD; NICHD

Document type: Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

(127 Refs.)

Record Date Created: 19820614

Record Date Completed: 19820614

8/7/4

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

05236047 PMID: 394636

Current status of thymosin research: evidence for the existence of a family of thymic factors that control T-cell maturation.

Low T L; Thurman G B; Chincarini C; McClure J E; Marshall G D; Hu S K; Goldstein A L

Annals of the New York Academy of Sciences (UNITED STATES) 1979, 332 p33-48, ISSN 0077-8923 Journal Code: 7506858

Document type: Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Thymosin fraction 5 contains several distinct hormonal-like factors which are effective in partially or fully inducing and maintaining immune function. Several of the peptide components of fraction 5 have been purified, sequenced and studied in assay systems designed to measure T-cell differentiation and function. These studies indicate that a number of the

purified peptides act on different subpopulations of T-cells (see Figure 1). Thymosin beta 3 and beta 4 peptides act on terminal deoxynucleotidyl transferase (TdT) negative precursor T-cells to induce TdT positive cells. Thymosin alpha 1 induces the formation of functional helper cells and conversion of Lyt- cells to Lyt 1+, 2+, 3+ cells. Thymosin alpha 7 induces the formation of functional suppressor T-cells and also converts Lyt- cells to Lyt 1+, 2+, 3+ cells. These studies have provided further evidence that the thymus secretes a family of distinct peptides which act at various sites of the maturation sequence of T-cells to induce and maintain immune function. Phase I and Phase II clinical studies with thymosin in the treatment of primary immunodeficiency diseases, autoimmune diseases, and cancer point to a major role of the endocrine thymus in the maintenance of immune balance and in the treatment of diseases characterized by thymic malfunction. It is becoming increasingly clear that immunological maturation is a process involving a complex number of steps and that a single factor initiating a single cellular event might not be reflected in any meaningful immune reconstitution unless it is the only peptide lacking. Given the complexity of the maturation sequence of T-cells and the increasing numbers of T-cell subpopulations that are being identified, it would be surprising if a single thymic factor could control all of the steps and populations involved. Rather, it would appear that the control of T-cell maturation and function involves a complex number of thymic-specific factors and other molecules that rigidly control the intermediary steps in the differentiation process. (90 Refs.)

Record Date Created: 19800426

Record Date Completed: 19800426

? ds

Set	Items	Description
S1	142	INTERFERON AND THYMOSIN
S2	142	Sort S1/ALL/PY
S3	62	HEPATITIS AND S2
S4	267563	FRAGMENT?
S5	0	S3 AND S4
S6	99	THYMOSIN AND DT=REVIEW? AND PY<1993
S7	267563	FRAGMENT?
S8	4	S6 AND S7
? s	s6 and s3	
	99	S6
	62	S3
S9	2	S6 AND S3
? t	s9/7/1	2

9/7/1

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

09441216 PMID: 1382288

Chronic hepatitis B and C. What is the status of drug therapy?

Wright T L

Division of Gastroenterology and Hepatology, School of Medicine,
University of California, San Francisco.

Postgraduate medicine (UNITED STATES) Sep 15 1992, 92 (4) p75-82,
ISSN 0032-5481 Journal Code: 0401147

Document type: Clinical Trial; Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Chronic hepatitis remains difficult to treat. Use of interferon has been successful against both hepatitis B and C viruses, but the outcome of long-term administration has yet to be determined. Not all patients respond to interferon, however, and some have side effects that cause them to discontinue therapy. Dr Wright discusses the results of studies to evaluate therapy with alpha, beta, and gamma interferon as well as with other agents, such as ribavirin, thymosin, and ursodeoxycholic acid. (32 Refs.)

Record Date Created: 19921022

Record Date Completed: 19921022

9/7/2

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

09420551 PMID: 1514436

Therapies for hepatitis B virus: current status and future possibilities.

Martin P; Friedman L S

Division of Gastroenterology and Hepatology, Jefferson Medical College,
Philadelphia, PA 19107.

Advances in experimental medicine and biology (UNITED STATES) 1992,
312 p111-20, ISSN 0065-2598 Journal Code: 0121103

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Alpha-interferon is the first agent with proven therapeutic efficacy in humans with chronic HBV infection. Obviously, further research is needed to clarify and expand the role of interferon in this setting. In addition, an overall response rate of less than 50% illustrates the need for continuing innovation in the treatment of HBV infection especially in patients with predictors of poor outcome. Despite the advent of effective vaccines

against HBV, this pathogen is likely to remain a source of serious human morbidity and mortality for the foreseeable future. Continuing efforts must be directed towards finding more effective therapies against HBV. A recent preliminary report suggests that thymosin, like interferon, an immune modulator, may also be efficacious in the treatment of chronic HBV and deserves further study. (35 Refs.)

Record Date Created: 19921001

Record Date Completed: 19921001

? ds

Set Items Description

S1 142 INTERFERON AND THYMOSIN

S2 142 Sort S1/ALL/PY

S3 62 HEPATITIS AND S2

S4 267563 FRAGMENT?

S5 0 S3 AND S4

S6 99 THYMOSIN AND DT=REVIEW? AND PY<1993

S7 267563 FRAGMENT?

S8 4 S6 AND S7

S9 2 S6 AND S3

? log hold

10jan05 13:16:33 User208669 Session D2679.2

\$8.22 2.569 DialUnits File155

\$0.00 156 Type(s) in Format 6

\$2.31 11 Type(s) in Format 7

\$2.31 167 Types

\$10.53 Estimated cost File155

\$2.75 TELNET

\$13.28 Estimated cost this search

\$13.66 Estimated total session cost 2.678 DialUnits

Logoff: level 04.20.00 D 13:16:33